Stocks Arena Pharmaceuticals Inc

More

  • pills_prescription_200.jpg

    I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.

  • obesity_man_200.jpg

    I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

  • Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.

  • Stock index futures pointed to a slightly higher open for Wall Street, with no significant economic news but quadruple-witching on the table.

  • cadeuses2.jpg

    Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.

  • Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • This company’s diabetes and obesity drug could generate huge returns for investors.

  • Mike and his sister.

    For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.

  • Amylin

    In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.

  • arena_pharm.jpg

    There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.

  • alli_logo.jpg

    Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

  • Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.

  • So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.

  • arena_pharm.jpg

    Blogging from the 14th NewsMakers in the Biotech Industry conference put on by BioCentury and Thomson Financial in Manhattan. It's a rare opportunity to spend a day getting possible story ideas and networking with sources.

  • Good morning all. Parker Robinson and James Kraber remain in the top two positions, with James holding the 2nd and 4th positions, and remember Deborah Taft? She made a strong move back into third place. Parker's portfolio value stands at $2,796,103.27, up $3,000 from Monday on bonus bucks.

  • Good morning all. Deborah Taft continues to hold the top position, but she is losing ground. And there's a new number two; Jason Kaplan. Jason gains 2nd place on his Worthington Industries trade forcing Chad Mazeika into 3rd place with only small gains on Mariner Energy and Sonus.